Hasten Biopharmaceutical is a verifiable, significant entity in the Chinese pharma sector, having raised $315M (Series D) and acquired a major drug portfolio from Takeda for ~$322M. While the project demonstrates 'Unicorn-level' real-world utility and traction, the user submission was low-quality (vague claims like 'everyone', 'most people'), necessitating a penalty on quality factors despite the verified high value of the enterprise.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline